Loomis Sayles & Co. L P Makes New Investment in Scholar Rock Holding Co. (NASDAQ:SRRK)

Loomis Sayles & Co. L P purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 776,665 shares of the company’s stock, valued at approximately $33,567,000. Loomis Sayles & Co. L P owned about 0.83% of Scholar Rock as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after buying an additional 269 shares during the last quarter. Quarry LP grew its stake in shares of Scholar Rock by 3,443.3% in the third quarter. Quarry LP now owns 4,500 shares of the company’s stock worth $36,000 after acquiring an additional 4,373 shares during the last quarter. Global Retirement Partners LLC increased its position in Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after acquiring an additional 766 shares during the period. Nisa Investment Advisors LLC raised its stake in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after purchasing an additional 1,031 shares during the last quarter. Finally, Amalgamated Bank boosted its holdings in Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after purchasing an additional 620 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Wedbush restated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $40.86.

Insider Buying and Selling

In other Scholar Rock news, insider Jing L. Marantz sold 5,655 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $249,951.00. Following the sale, the insider now directly owns 67,200 shares in the company, valued at $2,970,240. This represents a 7.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Tracey Sacco sold 6,500 shares of the business’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $33.08, for a total transaction of $215,020.00. Following the completion of the sale, the insider now owns 71,750 shares in the company, valued at $2,373,490. This represents a 8.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 299,772 shares of company stock valued at $11,245,798 over the last quarter. Corporate insiders own 19.20% of the company’s stock.

Scholar Rock Trading Up 3.7 %

Shares of SRRK stock opened at $33.36 on Friday. The firm has a fifty day moving average of $37.94 and a 200-day moving average of $32.72. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of -14.20 and a beta of 0.59. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.